Inflammatix’s TriVerity™ Test Secures NTAP Reimbursement from CMS for First-in-Class Severity Score Working in Concert with Bacterial and Viral Insights
SUNNYVALE, Calif., Aug. 4, 2025 /PRNewswire/ — Inflammatix, a leader in host-response diagnostics, today announced that its TriVerity™ Test has been granted New Technology Add-On Payment (NTAP) reimbursement by the Centers for Medicare & Medicaid Services (CMS) for fiscal year 2026. The NTAP decision, driven by TriVerity’s novel severity score—enabled by its FDA Breakthrough Device designation—recognizes the test’s unique clinical utility in helping emergency physicians rapidly and accurately triage patients with suspected infection or sepsis.
Unlike conventional diagnostics that focus solely on identifying pathogens, TriVerity delivers three integrated host-response scores—bacterial infection, viral infection, and illness severity—from a single blood draw within ~30 minutes. The test’s breakthrough advantage lies in how these scores work together to guide not just diagnosis, but disposition—supporting clinicians in determining what kind of infection a patient has, how sick they are, and what level of care they need right now.
